Tolebrutinib shows promise for treating non-relapsing secondary progressive multiple sclerosis
A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, demonstrated a 31%…